We must support Anvisa

Post-registration of medicines – opportunities and challenges

GGBIO task force: solution or palliative?

Anvisa: 25 years with many stories to tell

Anvisa's General Management of Medicines releases the 2023 Management Report

Real-world studies for drug registration: ANVISA guidelines

Find out about Anvisa's priorities for the next biennium

RDC 753 - New Regulatory Framework for the Registration of Synthetic Drugs.

WHAT ARE THE STEPS FOR OBTAINING AUTHORIZATION FOR CLINICAL STUDIES IN BRAZIL?

Important circumstances for the submission of drug registration in Brazil

What is the purpose of registration submission guide, based on data from scientific literature?

What are the main differences between the ICH guides and the ANVISA requirements?

ANVISA – Post-pandemic challenges and perspectives.

Clinical research in Brazil – New horizons, new challenges

ANVISA has just published the new version of the Cadifa Manual, but what were the main changes?

Unraveling the Abbreviated Development Path

Publication of the Public Consultation for the review of RDC 200 - what is new?

NEW REGULATORY FRAMEWORK OF API